Navigate Up
This page location is:
  • IFRS
    • Projects
      • Work plan for IFRSs
        • Financial Statement Presentation
          • Phase B - Presentation of items of OCI
            • Exposure draft [May 2010]
              • Comment letters
                • Pages
                  • CL125
Sign In
Comment letters
Welcome to the website of the IFRS Foundation and the IASB

Friday 24 May 2013

Search
Follow us (IFRSFoundation) on Twitter RSS Feed
  • Home
  • About us
    • About the organisation
    • Governance and accountability
    • Contact us
  • IFRS
    • Standard and interpretations (IFRSs and IFRICs)
    • IFRS for SMEs
    • IFRS taxonomy (XBRL)
    • Use around the world
    • IFRS education
    • IFRS translations
  • Standards development
    • Work plan for IFRSs
    • Work plan for interpretations (IFRICs)
    • Standard setting process
    • Interpretations process
    • High level summaries
  • Get involved
    • Comment on a proposal
    • Attend a conference or workshop
    • Outreach activities
    • Join the organisation
  • Stay informed
    • News
    • Board meeting summaries (IASB Update)
    • IFRIC meeting summaries (IFRIC Update)
    • Subscribe to email alerts
    • Manage your email alerts
    • Observe a meeting
    • Podcast summaries
    • Investor resources
  • Shop & eIFRS
    • Shop
    • eIFRS
Banner graphic

Skip Navigation LinksProjectsWork plan for IFRSsFinancial Statement PresentationPhase B - Presentation of items of OCIExposure draft [May 2010]Comment lettersCL125

Comment letters


 CL125

Submitted By: Andy Chard

Organisation: AstraZeneca Plc

Country:  

Date: 1/1/2009 11:00 AM

Attached Files:

Additional Page Content
  • AstraZeneca ED 2010 5 OCI comment letter.pdf

 © IFRS Foundation.

  • Privacy Policy
  • Terms & Conditions
  • Sitemap